ASCO 2024: Lung cancer roundup

Teclistamab continues to demonstrate deep and durable responses in relapsed/refractory multiple myeloma

Trial argues strongly for the development of 1st-line biomarker selected strategies in pancreatic ductal adenocarcinoma

Enfortumab vedotin improves efficacy outcomes in locally advanced or metastatic urothelial cancer across all exposure quartiles

ARV-766 well tolerated and shows promising clinical activity in metastatic castration-resistant prostate cancer

ASCO 2024: Highlights and analysis

ASCO 2024: Advances in NSCLC

Isatuximab shows benefit in transplant-ineligible patients with newly diagnosed multiple myeloma

Clinical behaviour of breast cancer in young BRCA carriers and prognostic impact of the timing of genetic testing

ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma

Durvalumab after chemoradiotherapy improves survival in limited-stage SCLC

Chemotherapy before and after surgery may be new standard treatment for some patients with oesophageal cancer